Myeloma expression systems

被引:43
作者
Yoo, EM
Chintalacharuvu, KR
Penichet, ML
Morrison, SL
机构
[1] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
关键词
myeloma cells; monoclonal antibodies; antibody engineering; protein expression;
D O I
10.1016/S0022-1759(01)00559-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Myeloma expression systems have been utilized successfully for the production of various recombinant proteins. In particular, myeloma cell lines have been exploited to express a variety of different antibodies for diagnostic applications as well as in the treatment of various human diseases. The use of myeloma cells for antibody production is advantageous because they are professional immunoglubulin-secreting, cells and are able to make proper post-translational modifications, Proper glycosylation has been shown to be important for antibody function. Advances in genetic engineering and molecular biology techniques have made it possible to isolate murine and human variable regions of almost any desired specificity. Antibodies and antibody variants produced in myeloma cells have been extremely helpful in elucidating the amino acid residues and structural motifs that contribute to antibody function. Because of their domain nature, immunoglobulin genes can be easily manipulated to produce chimeric or humanized antibodies. These antibodies are less immunogenic in humans and also retain their specificity for antigen and biologic properties. In addition, novel proteins in which antibodies are fused to non-immunoglobulin sequences as well as secretory IgA have been produced in myeloma cells. (C) 2002 Elsevier Science B,V. All rights reserved.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 176 条
[1]   Transporting therapeutics across the blood-brain barrier [J].
Abbott, NJ ;
Romero, IA .
MOLECULAR MEDICINE TODAY, 1996, 2 (03) :106-113
[2]   Edrecolomab (monoclonal antibody 17-1A) [J].
Adkins, JC ;
Spencer, CM .
DRUGS, 1998, 56 (04) :619-626
[3]  
AHOUSE JJ, 1993, J IMMUNOL, V151, P6076
[4]   A LYMPHOCYTE-SPECIFIC CELLULAR ENHANCER IS LOCATED DOWNSTREAM OF THE JOINING REGION IN IMMUNOGLOBULIN HEAVY-CHAIN GENES [J].
BANERJI, J ;
OLSON, L ;
SCHAFFNER, W .
CELL, 1983, 33 (03) :729-740
[5]   HIGH-LEVEL EXPRESSION OF A RECOMBINANT ANTIBODY FROM MYELOMA CELLS USING A GLUTAMINE-SYNTHETASE GENE AS AN AMPLIFIABLE SELECTABLE MARKER [J].
BEBBINGTON, CR ;
RENNER, G ;
THOMSON, S ;
KING, D ;
ABRAMS, D ;
YARRANTON, GT .
BIO-TECHNOLOGY, 1992, 10 (02) :169-175
[6]   An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response [J].
Becker, JC ;
Varki, N ;
Gillies, SD ;
Furukawa, K ;
Reisfeld, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7826-7831
[7]   T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy [J].
Becker, JC ;
Pancook, JD ;
Gillies, SD ;
Furukawa, K ;
Reisfeld, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) :2361-2366
[8]   Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy [J].
Becker, JC ;
Varki, N ;
Gillies, SD ;
Furukawa, K ;
Reisfeld, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12) :2801-2804
[9]   In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells [J].
Berdoz, J ;
Blanc, CT ;
Reinhardt, M ;
Kraehenbuhl, JP ;
Corthésy, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :3029-3034
[10]  
BETTER M, 1989, METHOD ENZYMOL, V178, P476